Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.39 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 1/20 | 0.39 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1981243 | 0.88 | KMT2A (0.50) | KMT2AL3MBTL1TSHRHSP90AA1POLB | |
| SCHEMBL5005151 | 0.81 | KMT2A (0.56) | KMT2AL3MBTL1TSHRHSP90AA1POLB | |
| SCHEMBL3907606 | 0.81 | KMT2A (0.56) | KMT2AL3MBTL1TSHRHSP90AA1POLB | |
| SCHEMBL28838729 | 0.81 | KMT2A (0.56) | KMT2AL3MBTL1TSHRHSP90AA1POLB | |
| SCHEMBL1497667 | 0.81 | KMT2A (0.43) | KMT2AL3MBTL1TSHRHSP90AA1POLB | |
| SCHEMBL14001959 | 0.81 | KMT2A (0.56) | KMT2AL3MBTL1TSHRHSP90AA1POLB | |
| SCHEMBL14562685 | 0.78 | KMT2A (0.53) | KMT2AL3MBTL1TSHRHSP90AA1POLB | |
| SCHEMBL2857258 | 0.77 | KMT2A (0.51) | KMT2AL3MBTL1TSHRHSP90AA1POLB | |
| SCHEMBL29700667 | 0.77 | L3MBTL1 (0.36) | KMT2AL3MBTL1TSHRHSP90AA1POLB | |
| SCHEMBL1911510 | 0.76 | KMT2A (0.51) | KMT2AL3MBTL1TSHRHSP90AA1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109824756-A | Contain 4-(benzenesulfonyl) phenylalanine derivative and the preparation method and application thereof of piperazine -2- ketone | 山东大学 | 2019-05-31 | — | — | CN | claimed |
| CN-103619865-A | Certain chemical entities, compositions, and methods | SUZHOU NEUPHARMA CO LTD | 2014-03-05 | — | — | CN | claimed |
| CN-102656179-A | Bufalin derivatives, pharmaceutical compositions and uses thereof | SUZHOU NEUPHARMA CO LTD | 2012-09-05 | — | — | CN | claimed |
| WO-2012027957-A1 | BUFALIN DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF | SUZHOU NEUPHARMA CO., LTD. (CN) | 2012-03-08 | — | — | WO | claimed |
| US-7425638-B2 | Cis-imidazolines | HOFFMANN-LA ROCHE INC. (US) | 2008-09-16 | — | — | US | claimed |
| JP-2008535876-A | — | — | 2008-09-04 | — | — | JP | claimed |
| CN-101160313-A | Aminopyrazole derivatives, their preparation and use as pharmaceutical agents | HOFFMANN LA ROCHE (CH) | 2008-04-09 | — | — | CN | claimed |
| EP-1879894-A1 | AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-01-23 | — | — | EP | claimed |
| WO-2006108489-A1 | AMINOPYRAZOLE DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-19 | — | — | WO | claimed |
| EP-1638942-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-03-29 | — | — | EP | claimed |
| WO-2005003097-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | claimed |
| US-20040259884-A1 | Cis-imidazolines | HALEY GREGORY JAY (US) | 2004-12-23 | — | — | US | claimed |
| WO-2025264844-A1 | HETEROCYCLIC GPR52 MODULATORS AND METHODS OF USE THEREOF | LIEBER INSTITUTE, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025202022-A9 | ANTICANCER MACROCYCLIC QUINAZOLINE-BASED INHIBITORS OF THE INERACTION BETWEEN RAS AND SOS1 | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-26 | — | — | WO | disclosed |
| US-20250332266-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | BEIGENE SWITZERLAND GMBH (CH) | 2025-10-30 | — | — | US | disclosed |
| EP-4638455-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2025-10-29 | — | — | EP | disclosed |
| WO-2005103054-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCRI ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-03 | — | — | WO | disclosed |
| WO-2005003097-A1 | CIS-2,4,5-TRIARYL-IMIDAZOLINES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-01-13 | — | — | WO | disclosed |
| US-20040259884-A1 | Cis-imidazolines | HALEY GREGORY JAY (US) | 2004-12-23 | — | — | US | disclosed |
| CN-1291892-A | Substituted oxoazaheterocyclyl factor Xa inhibitors | AWENTIS PHARMACEUTICAL INC (US) | 2001-04-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259884-A1 | Cis-imidazolines | TP53, MDM2, TP53BP1 | KMT2A 4125/4885L3MBTL1 579/4885TSHR 2923/4885 |
| US-20250332266-A1 | COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE | EGFR, ERBB2, ERBB3 | KMT2A 2303/4885L3MBTL1 1504/4885TSHR 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.